Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety and Efficacy of Vedolizumab in Pediatric Uclerative Colitis in Comparison With Standard Biological Therapy With Infliximab

NCT06614387 is registered in ClinicalTrials.gov with JAROSLAW KIERKUS as lead sponsor.

NCT NCT06614387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety and Efficacy of Vedolizumab in Pediatric Uclerative Colitis in Comparison With Standard Biological Therapy With Infliximab
Lead sponsor
JAROSLAW KIERKUS
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2024
Completion date
November 30, 2028
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis